Stocktoria
Aurinia Pharmaceuticals Inc. AUPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2001-07-16
Aurinia Pharmaceuticals Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M |
| R&D expense | $32.5M | $20.8M | $49.6M | $45.0M | $51.1M |
| SG&A expense | — | — | $195.0M | $196.4M | $173.5M |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M |
| Interest expense | — | — | $2.8M | $0 | $0 |
| Income tax | -$173.0M | $1.7M | $551,000 | $1.8M | $760,000 |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M |
| EPS (diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M |
| Cash & equivalents | $80.2M | $83.4M | $48.8M | $94.1M | $231.6M |
| Inventory | $45.7M | $39.2M | $39.7M | $24.8M | $19.3M |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M |
| Shareholders' equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M |
Source: SEC EDGAR filings · CIK 0001600620 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.